Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Biasi, A. Rocino, E. Miraglia, L. Mastrullo, A. Quirino (1991)
The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate.Blood, 78 8
Martha, M., Eibl, Rafi, Ahmad, Hermann, Wolf, Yendra, Linnau, Josef, W., Mannhalter (1987)
A component of factor VIII preparations which can be separated from factor VIII activity down modulates human monocyte functions.Blood, 69 4
P. Mortimer, N. Luban, J. Kelleher, B. Cohen (1983)
TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATESThe Lancet, 322
Hanley Hanley (1983)
Lippman‐Hand A. If nothing goes wrong, is everything all right? Interpreting zero numeratorsJAMA, 249
M. Stirling, J. Murray, P. Mackay, S. Black, J. Peutherer, C. Ludlam (1983)
Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971-1979.Journal of Clinical Pathology, 36
H. Behre, C. Orthner, Hernan Nunez, Harlan Anderson, Demetrios Triantaphyllopoulos, D. Kosow (2005)
Coagulation Factor IX Concentrate : Method of Preparation and Assessment of Potential In Vivo Thrombogenicity in Animal Models
J. Cash (1991)
High potency factor VIII concentrates: value not proved?British Medical Journal, 303
G. Kuo, Q. Choo, H. Alter, G. Gitnick, A. Redeker, R. Purcell, T. Miyamura, J. Dienstag, M. Alter, C. Stevens (1990)
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.Science, 244 4902
D. Austen (1979)
The Chromatographic Separation of Factor VIII on Aminohexyl SepharoseBritish Journal of Haematology, 43
(1992)
Human parvovirus B 19 infection in hemophiliacs first infused with two high - purity , virally attenuated factor VIII con centrates
H. Kim, L. Matts, J. Eisele, M. Czachur, P. Saidi (1991)
Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.Seminars in hematology, 28 3 Suppl 6
D. Aronson (1990)
The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia ATransfusion, 30
Orthopaedic Hospital, 2400 South Flower Street
MMWR Morb Mortal Wkly Rep, 31
B. Macik, J. Hohneker, H. Roberts, Anne Griffin (1989)
Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitorAmerican Journal of Hematology, 32
Gilbert White, Campbell McMillan, Henry Kingdon, Charles Shoemaker (1989)
Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.The New England journal of medicine, 320 3
P. Mannucci, K. Schimpf, T. Abe, L. Aledort, K. Anderle, D. Brettler, M. Hilgartner, P. Kernoff, M. Kunschak, C. McMillan, F. Preston, G. Rivard (1992)
Low risk of viral infection after administration of vapor‐heated factor VIII concentrateTransfusion, 32
M. Booy, W. Riethorst, A. Faber, J. Over, Boudewijn König (1989)
Affinity Purification of Plasma Proteins: Characterization of Six Affinity Matrices and their Application for the Isolation of Human Factor VIIIThrombosis and Haemostasis, 61
Ehrenkranz Nj, J. Rubini, R. Gunn, Horsburgh Cr, T. Collins, U. Hasiba, W. Hathaway, W. Doig, R. Hopkins, J. Elliott (1982)
Pneumocystis carinii pneumonia among persons with hemophilia A.MMWR. Morbidity and mortality weekly report, 31 27
D. Thomas (1988)
REDUCING THE RISK OF VIRUS TRANSMISSION BY BLOOD PRODUCTSBritish Journal of Haematology, 70
K. Pasi, F. Hill (1990)
In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purityBritish Journal of Haematology, 76
R. Madhok, John Smith, Andrew Jenkins, G. Lowe (1991)
T cell sensitization to factor VIII in haemophilia A?British Journal of Haematology, 79
(1983)
rological evidence that dry heating of clotting factor concentrates prevents transmission of nonA , non - B hepatitis
P. Griffiths, S. Talbot (1971)
Diagnosis of Established Deep Vein ThrombosisBritish Medical Journal, 4
D. Piszkiewicz, L. Bourret, M. Lieu, K. Hattley, W. Thomas, C. Cabradilla, H. Kingdon, D. Ménaché (1987)
Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.Thrombosis research, 47 2
(1991)
Anti - HCV prevalence in relation to type and amount of clotting factor therapy in congenital clotting disorders ( abstract )
R. Cuthbert, C. Ludlam, C. Steel, D. Beatson, J. Peutherer (1992)
Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapyBritish Journal of Haematology, 80
MMWR Morb Mortal Wkly Rep, 35
(1988)
Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.Lancet, 2 8615
R. Thorpe, P. Dilger, N. Dawson, T. Barrowcliffe (1989)
Inhibition of interleuk:in‐2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacsBritish Journal of Haematology, 71
M. Colombo, V. Carnelli, C. Gazengel, P. Mannucci, G. Savidge, K. Schimpf (1985)
TRANSMISSION OF NON-A, NON-B HEPATITIS BY HEAT-TREATED FACTOR VIII CONCENTRATEThe Lancet, 326
M. Ragni, A. Winkelstein, L. Kingsley, J. Spero, J. Lewis (1987)
1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and BBlood, 70
(1988)
Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VlII inhibitor
N. Frickhofen, J. Abkowitz, M. Safford, J. Berry, J. Antunez-de-Mayolo, A. Astrow, Robert Cohen, I. Halperin, L. King, D. Mintzer, B. Cohen, N. Young (1990)
Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.Annals of internal medicine, 113 12
Y. Sultan, M. Algiman (1990)
Treatment of factor VIII inhibitors.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1 2
J. Smith, E. Bidwell (1979)
Therapeutic materials used in the treatment of coagulation defects.Clinics in haematology, 8 1
J. Eibl, A. Kaeser, N. Heimburger, H. Karges, B. Horowitz, J. Lundblad, M. Mozen, P. Mannucci, M. Morfini, J. Morgenthaler, D. Piszkiewicz, W. Stephan (1988)
Ways to reduce the risk of transmission of viral infections by plasma and plasma products. A comparison of methods, their advantages and disadvantages.Vox sanguinis, 54 4
J. Kreiss, L. Kitchen, H. Prince, C. Kasper, M. Essex (1985)
Antibody to human T-lymphotropic virus type III in wives of hemophiliacs. Evidence for heterosexual transmission.Annals of internal medicine, 102 5
U. Hasiba, J. Spero, J. Lewis (1977)
Chronic Liver Dysfunction in Multitransfused HemophiliacsTransfusion, 17
P. Mannucci, K. Bauer, A. Gringeri, S. Barzegar, E. Santagostino, F. Tradati, R. Rosenberg (1991)
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrateBritish Journal of Haematology, 79
Q. Choo, G. Kuo, A. Weiner, L. Overby, D. Bradley, M. Houghton (1989)
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.Science, 244 4902
J. Addiego, E. Gomperts, Liu Shu-Len, Patricia Bailey, S. Courter, Martin Lee, G. Neslund, H. Kingdon, M. Griffith (1992)
Treatment of Hemophilia A with a Highly Purified Factor VIII Concentrate Prepared by Anti-FVIIIc Immunoaffinity ChromatographyThrombosis and Haemostasis, 67
V. Carnelli, E. Gomperts, A. Friedman, L. Aledort, M. Hilgartner, S. Dietrich, E. Fedor (1987)
Assessment for evidence of non A-non B hepatitis in patients given n-heptane-suspended heat-treated clotting factor concentrates.Thrombosis research, 46 6
D. Brettler, H. Alter, J. Dienstag, A. Forsberg, P. Levine (1990)
Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients.Blood, 76 1
M. Horowitz, B. Horowitz, C. Rooks, M. Hilgartner (1988)
VIRUS SAFETY OF SOLVENT/DETERGENT-TREATED ANTIHAEMOPHILIC FACTOR CONCENTRATEThe Lancet, 332
(1976)
Direct and indirect effects of chronic plasma protein infusion
P. Mannucci, A. Gringeri, R. Biasi, F. Baudo, M. Morfini, N. Ciavarella (1992)
Immune Status of Asymptomatic HIV-Infected Hemophiliacs: Randomized, Prospective, Two-Year Comparison of Treatment with a High-Purity or an Intermediate-Purity Factor VIII ConcentrateThrombosis and Haemostasis, 67
B. Horowitz, M. Wiebe, A. Lippin, J. Vandersande, M. Stryker (1985)
Inactivation of viruses in labile blood derivatives. II. Physical methodsTransfusion, 25
MMWR Morb Mortal Wkly Rep, 38
Kasper Kasper (1975)
Thromboembolic complicationsThromb Diath Haemorrh, 33
W. Fricke, L. Augustynm, D. Lawrence, A. Brownstein, A. Kramer, B. Evatt (1992)
Human immunodeficiency virus infection due to clotting factor concentrates: results of the Seroconversion Surveillance ProjectTransfusion, 32
(1976)
Unsolved therapeutic problems in hemophilia. Dept of Health
M. Pistello, L. Ceccherini-Nelli, N. Cecconi, M. Bendinelli, F. Panicucci (1991)
Hepatitis C virus seroprevalence in Italian haemophiliacs injected with virus‐inactivated concentrates: Five year follow‐up and correlation with antibodies to other virusesJournal of Medical Virology, 33
R. Schwartz, C. Abildgaard, L. Aledort, S. Arkin, A. Bloom, H. Brackmann, D. Brettler, H. Fukui, M. Hilgartner, M. Inwood, C. Kasper, P. Kernoff, P. Levine, J. Lusher, P. Mannucci, I. Scharrer, M. Mackenzie, Nazreen Pancham, Harng Kuo, R. Allred (1990)
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.The New England journal of medicine, 323 26
E. Gomperts (1986)
Procedures for the inactivation of viruses in clotting factor concentratesAmerican Journal of Hematology, 23
D. Ménaché (1976)
Report of the Task Force on the Clinical Use of Factor IX ConcentratesThrombosis and Haemostasis, 35
Levine Levine (1988)
Factor VIII:C purified from plasma via monoclonal antibodies: human studiesSemin Hematol, 25
D. Brettler, A. Forsberg, P. Levine, L. Aledort, M. Hilgartner, C. Kasper, J. Lusher, C. McMillan, H. Roberts (1989)
The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.Archives of internal medicine, 149 6
Other members of the American Association of Blood Banks Transfusion Practices Committee are
Mannucci Mannucci, Schimpf Schimpf, Abe Abe (1992)
Low risk of viral infection after administration of vapor‐heated factor VIII concentrate. International Investigator GroupTransfusion, 32
J. Goedert, C. Kessler, L. Aledort, R. Biggar, W. Andes, Gilbert White, J. Drummond, Kampala Vaidya, D. Mann, M. Eyster, M. Ragni, M. Lederman, Alan Cohen, G. Bray, P. Rosenberg, R. Friedman, M. Hilgartner, W. Blattner, B. Kroner, M. Gail (1989)
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia.The New England journal of medicine, 321 17
White nd, Lundblad Rl, Kingdon Hs (1979)
Prothrombin complex concentrates: preparation, properties, and clinical uses.Current topics in hematology, 2
C. Vermot‐Desroches, D. Rigal, Christian Blourde, J. Bernaud (1992)
Immunosuppressive property of a very high purity antihaemophilic preparation: a low molecular weight component inhibits an early step of PHA induced cell activationBritish Journal of Haematology, 80
A. Prince, B. Horowitz, B. Brotman, T. Huima, L. Richardson, M. Ende (1984)
Inactivation of Hepatitis B and Hutchinson Strain Non‐A, Non‐B Hepatitis Viruses by Exposure to Tween 80 and Ether 1Vox Sanguinis, 46
Doreen Brettler, Peter Levine (1989)
Factor concentrates for treatment of hemophilia: which one to choose?Blood, 73 8
S. Stein, B. Evatt, J. Mcdougal, D. Lawrence, R. Holman, R. Ramsey, T. Spira (1985)
A longitudinal study of patients with hemophilia: immunologic correlates of infection with HTLV-III/LAV and other viruses.Blood, 66 4
(1991)
CD 4 cells in HIV - 1 infected hemophiliacs : effect of factor VIII concentrates
J., S. McDougal, L. Martin, S. Cort, M. Mozen, C. Heldebrant, B. Evatt (1985)
Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.The Journal of clinical investigation, 76 2
D. Heinrich, R. Kotitschke, H. Berthold (1982)
Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB).Thrombosis research, 28 1
D. Lawrence (1990)
A review of clinical studies evaluating the efficacy of HIV inactivation methods.Progress in clinical and biological research, 324
Consistently normal CD 4 + , CD 8 + levels in haemophilic boys only treated with a virally safe factor VIlI concentrate ( BPL 8 Y )
Finlayson Finlayson, Tankersley Tankersley (1990)
Anti‐HCV screening and plasma fractionation: the case against (letter)Lancet, 335
C. Kasper (1975)
Thromboembolic ComplicationsThrombosis and Haemostasis, 33
K. Schimpf, P. Mannucci, W. Kreutz, H. Bragkmann, C. Auerswald, Nicola Ciavarella, J. Mößeler, V. Derosa, B. Kraus, Ch. Bruegkmann, G. Mancuso, U. Mittler, F. Haschke, Massimo Morfini (1987)
Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions.The New England journal of medicine, 316 15
J. Hanley, A. Lippman‐Hand (1983)
If nothing goes wrong, is everything all right? Interpreting zero numerators.JAMA, 249 13
U. Hedner, S. Bjoern, S. Bernvil, L. Tengborn, L. Stigendahl (1989)
Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors.Haemostasis, 19 6
J. Finlayson, D. Tankersley (1990)
Anti-HCV screening and plasma fractionation: the case againstThe Lancet, 335
(1983)
Hypoplastic anemia in a hemophiliac first infused with a solvent / detergent treated fac tor VIII concentrate : the role of human B 19 parvovirus ( letter )
B. Horowitz, M. Wiebe, A. Lippin, M. Stryker (1985)
Inactivation of viruses in labile blood derivatives. I. Disruption of lipid‐enveloped viruses by tri(n‐butyl)phosphate detergent combinationsTransfusion, 25
(1989)
Risks associated with human parvovirus B19 infection.MMWR. Morbidity and mortality weekly report, 38 6
Kernoff Kernoff, Miller Miller, Savidge Savidge, Machin Machin, Dewar Dewar, Preston Preston (1987)
Reduced risk of non‐A, non‐B hepatitis after a first exposure to “wet heated” factor VIII concentrateBr J Haematol, 67
(1986)
Non-A, non-B hepatitis associated with a factor IX complex infused during cardiovascular surgery--Arizona.MMWR. Morbidity and mortality weekly report, 35 24
A. Johnson, R. Mathews, A. Fulton (2009)
Fractionation of factor VIII and IX--an overview.Scandinavian journal of haematology. Supplementum, 40
P. Mannucci, A. Zanetti, M. Colombo (1988)
Prospective study of hepatitis after factor VIII concentrate exposed to hot vapourBritish Journal of Haematology, 68
J. Lusher (1991)
Thrombogenicity associated with factor IX complex concentrates.Seminars in hematology, 28 3 Suppl 6
Lancet, 2
KASPER, J.M. LUSHER, THE TRANSFUSION AND PRACTICES COMMITTEE such changes were incremental, requiring only amendments to licenses, while brand names remained the same. New brand names entered the vocabulary when additional fractionators entered the concentrate market. During the 198Os, however, changes in concentrates were major and relatively frequent and were due, for the most part, to efforts to prevent the transmission of bloodborne viral infections. Brand names were modified, usually by suffixes designating the method of purification or of virus inactivation. At times, multiple versions of one brand were on the market simultaneously. Only a few coagulation linguists could interpret the Babel of nomenclature. Confounding the perplexity, additional methods for screening donors were introduced and mandated at different times during the same epoch. A given brand might be manufactured from plasma screened by certain means one year, and by additional means the next year, with no change in brand name. Furthermore, nearly all concentrates had an outdate period of 2 years, and thus, concentrates made from plasma collected according to the standards of prior years often were on the market at the same time as concentrates made from plasma collected according to current standards. This report describes the
Transfusion – Wiley
Published: May 1, 1993
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.